Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene reports business update and end Q3 2020 financial position
information fournie par Boursorama CP 05/11/2020 à 17:45
Ajouter Boursorama à vos sources

­- Promising clinical data for TG4001 - late breaker abstract at SITC 2020
­- Advanced technological leadership with the myvac® platform: two clinical trials in patients with solid tumors initiated in January 2020
­- Initial translational data confirm that I.V. TG6002 can induce the production of a chemotherapy agent (5-FU) in the tumor
- Invir.IO(TM) -based BT-001 on track to enter the clinic before the end of 2020
- €45.3 million in cash and cash equivalents as of September 30, 2020, following the partial sale of stake in Tasly BioPharmaceuticals

Strasbourg, France, November 5, 2020, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update for the quarter ending September 30, 2020.

.../...

Valeurs associées

TRANSGENE
0,8020 EUR Euronext Paris -0,62%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
Pétrole Brent
89,37 -0,02%
CAC 40
8 401,18 +0,98%
Or
4 458,8 0,00%
EUR/USD SPOT
1,15822 0,00%
HAFFNER ENERGY
0,543 +15,04%
Chargement...

Pages les plus populaires

L'offre BoursoBank